KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Biotech

Celltrion to develop oral autoimmune disease treatment with US firm

Jinju by Jinju
PUBLISHED: June 5, 2023 UPDATED: June 5, 2023
in Biotech, South Korea
0
Celltrion

Celltrion, a leading biopharmaceutical company in South Korea, has partnered with Rani Therapeutics, a US-based clinical-stage biotech company. According to Yonhap, under their new partnership, they will jointly develop ‘oral adalimumab’ which is an oral autoimmune disease treatment with the development name RT-105.

Celltrion has previously developed the CT-P17 (adalimumab), a biosimilar of Humira. This prevalent autoimmune disease medication for rheumatoid arthritis, spondyloarthritis, and psoriasis has obtained marketing permission from the European Medicines Agency (EMA), an Amsterdam-based agency responsible for the evaluation and supervision of pharmaceutical products in European countries and approval of USA’s Food and Drug Administration (FDA), a federal agency of health.

The new partnership also aims to transform the injectable CT-P17 into an oral pill version, RT-105. Rani Therapeutics specializes in developing technology for the oral delivery of biological drugs and enhancing patient recovery. They will assist in converting protein and antibody formulations into oral formulations.

As per the terms and conditions, Celltrion has the responsibility to provide CT-P17 for the development of RT-105. It also has the first option to purchase global development. It furthermore has the opportunity to commercialize the rights depending on the first phases’ outcomes.

This collaboration builds upon a previous agreement between the two companies in January of this year for the development of an oral formulation of RT-111, an oral monoclonal antibody treatment. The Humira market, currently valued at $28 trillion, anticipates significant changes brought by Celltrion.

Celltrion’s Yuflyma receives FDA approval

In March this year, the US approved Celltrion-made Yuflyma, a citrate-free formulation of Humira biosimilar. Yuflyma offers an alternative treatment option for patients. In the US, about 80 percent of patients treated with Humira are dependent on high-concentration as well as citrate-free formulations like Yuflyma.

In the USA, Humira is widely utilized as a treatment for autoimmune diseases. It generated global sales of approximately $21.37 billion in 2022. The US market accounts for over 85 percent of global sales, amounting to $18.6 billion. The intake of Humira is therefore the highest in the world.

Celltrion is also actively seeking collaborations with domestic and international biotech firms. The company additionally is committed to innovation. It plans to expand treatment modalities with specific formulations in the coming months, according to a representative from Celltrion.

 

Tags: antibodyantibody treatmentbiotechMOUtherapeuticsUS market

Related Posts

South Korea, BlackRock Team Up to Build Hyperscale AI Data Center Hub
Data Center

South Korea, BlackRock Team Up to Build Hyperscale AI Data Center Hub

October 1, 2025
Global API Standardization Gets a Push with SK Telecom–Aduna Partnership
AI

Global API Standardization Gets a Push with SK Telecom–Aduna Partnership

September 23, 2025
$12B Crypto Wave: How Young Koreans Are Shaping Global Markets
Cryptocurrency

$12B Crypto Wave: How Young Koreans Are Shaping Global Markets

September 1, 2025
Caught Between Giants: How U.S. Export Controls Reshape South Korea’s Semiconductor Strategy
Samsung

Caught Between Giants: How U.S. Export Controls Reshape South Korea’s Semiconductor Strategy

September 1, 2025
Samsung and SK Hynix Face New U.S. Licensing Rules for Chinese Chip Plants
China

Samsung and SK Hynix Face New U.S. Licensing Rules for Chinese Chip Plants

August 31, 2025
South Korea Eyes Global AI Leadership with Record 8.1% Budget Hike
AI

South Korea Eyes Global AI Leadership with Record 8.1% Budget Hike

August 30, 2025
No Result
View All Result

Most Popular

  • Ride-Hailing Rivalry: Kakao and Uber Bet on Membership Services in Korea

    0 shares
    Share 0 Tweet 0
  • Kakao Mobility Faces $10.5 Million Fine for Limiting Competitors’ Access to Taxi Platform

    0 shares
    Share 0 Tweet 0
  • Korea’s Navigation Battle Heats Up: Naver and Kakao vs. Google maps

    0 shares
    Share 0 Tweet 0
  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Naver Launches 3D Street View for Immersive Navigation Experience

    0 shares
    Share 0 Tweet 0
  • KakaoTalk to Adopt Instagram-Style Feed in Major 2025 Redesign

    0 shares
    Share 0 Tweet 0
  • Naver Maps Launches Guide in English, Chinese, and Japanese to Enhance Travel Experience for Tourists

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Naver Unveils Asia’s Largest Data Center, GAK Sejong, for Tech Innovation

    0 shares
    Share 0 Tweet 0
  • LG’s Return to Smartphones: A New AI Collaboration with Samsung

    0 shares
    Share 0 Tweet 0

PRODUCTS

[ads_amazon]

TOPICS

  • Naver
  • Kakao
  • Nexon
  • Netmarble
  • NCsoft
  • Samsung
  • Hyundai

FREE NEWSLETTER

FOLLOW US

  • About Us
  • Cookie policy
  • home
  • homepage
  • mainhome
  • Our Services
  • Privacy Policy
  • Terms of Use

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |